Company profile
AMGEN INC
NASDAQ:AMGNBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (69)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REPATHA | approved | $953.0MQ2 2026 | 39 | approved |
| REPATHA | approved | $953.0MQ2 2026 | 39 | approved |
| PROLIA | approved | $759.0MQ2 2026 | 54 | approved |
| EVENITY | approved | $714.0MQ2 2026 | 0 | — |
| OTEZLA | approved | $491.0MQ2 2026 | 45 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (950)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00840333 | phase1 | completed | 2009-04-01 | 2009-12-01 | Amgen | "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients" |
| NCT00527085 | phase2 | completed | 2001-10-01 | 2003-08-01 | Amgen | 12-month Study of AMG 073 in Renal Osteodystrophy |
| NCT00356356 | phase3 | completed | 2002-04-01 | 2006-08-01 | Amgen | 16.0040 Ankylosing Spondylitis Study |
| NCT00803712 | phase4 | completed | 2009-02-01 | 2010-12-09 | Amgen | 20070360 Incident Dialysis |
| NCT01568216 | phase2 | terminated | 2012-05-01 | 2013-06-01 | Amgen | 20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms |
FDA applications (30)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 210745 | 2025-08-29 | NDA | AMGEN INC | |||||
Loading… | ||||||||
| BLA 761298 | 2024-08-23 | BLA | AMGEN INC. | |||||
Loading… | ||||||||
| BLA 761333 | 2024-05-28 | BLA | AMGEN INC. | |||||
Loading… | ||||||||
| BLA 761344 | 2024-05-16 | BLA | AMGEN INC. | |||||
Loading… | ||||||||
| BLA 761285 | 2023-10-31 | BLA | AMGEN INC. | |||||
Loading… | ||||||||